Thomas E Renau

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa
    Thomas E Renau
    Essential Therapeutics, Inc, 850Maude Avenue, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 12:763-6. 2002
  2. ncbi MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization
    Kiyoshi Nakayama
    Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co, Ltd, 1 16 13, Kitakasai, Edogawa, Tokyo, 134 8630, Japan
    Bioorg Med Chem Lett 13:4201-4. 2003
  3. ncbi Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa
    Thomas E Renau
    Essential Therapeutics, Inc, 850Maude Avenue, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 13:2755-8. 2003
  4. ncbi The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges
    Thomas E Renau
    Roche Palo Alto, 3431 Hillview Ave, Palo Alto, CA 94304, USA
    Curr Opin Investig Drugs 5:34-9. 2004
  5. ncbi The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors
    William J Watkins
    Essential Therapeutics, Inc, 850Maude Ave, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 13:4241-4. 2003
  6. ncbi Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives
    William J Watkins
    Essential Therapeutics, Inc, 850 Maude Ave, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 14:5133-7. 2004
  7. ncbi Molecular basis for fungal selectivity of novel antimitotic compounds
    Thomas Lila
    Essential Therapeutics, Mountain View, California 94043, USA
    Antimicrob Agents Chemother 47:2273-82. 2003
  8. ncbi MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds
    Kiyoshi Nakayama
    Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co, Ltd, 1 16 13, Kitakasai, Edogawa, Tokyo 134 8630, Japan
    Bioorg Med Chem Lett 13:4205-8. 2003

Collaborators

Detail Information

Publications8

  1. ncbi Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa
    Thomas E Renau
    Essential Therapeutics, Inc, 850Maude Avenue, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 12:763-6. 2002
    ..A number of the new analogues were as active or more active than the lead, demonstrating that a peptide backbone is not essential for activity...
  2. ncbi MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization
    Kiyoshi Nakayama
    Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co, Ltd, 1 16 13, Kitakasai, Edogawa, Tokyo, 134 8630, Japan
    Bioorg Med Chem Lett 13:4201-4. 2003
    ..Early leads lacked activity in animal models, and efforts to improve solubility and reduce serum protein binding by the introduction of polar groups are discussed...
  3. ncbi Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa
    Thomas E Renau
    Essential Therapeutics, Inc, 850Maude Avenue, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 13:2755-8. 2003
    ....
  4. ncbi The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges
    Thomas E Renau
    Roche Palo Alto, 3431 Hillview Ave, Palo Alto, CA 94304, USA
    Curr Opin Investig Drugs 5:34-9. 2004
    ..The following review examines the promise that PDE4 inhibitors may hold for the treatment of these diseases...
  5. ncbi The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors
    William J Watkins
    Essential Therapeutics, Inc, 850Maude Ave, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 13:4241-4. 2003
    ..The ratio of drug levels in tissue versus serum was not significantly reduced in any of the active analogues examined...
  6. ncbi Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives
    William J Watkins
    Essential Therapeutics, Inc, 850 Maude Ave, Mountain View, CA 94043, USA
    Bioorg Med Chem Lett 14:5133-7. 2004
    ....
  7. ncbi Molecular basis for fungal selectivity of novel antimitotic compounds
    Thomas Lila
    Essential Therapeutics, Mountain View, California 94043, USA
    Antimicrob Agents Chemother 47:2273-82. 2003
    ..Features of the proposed binding site explain the observed fungal tubulin specificity of the series and are consistent with structure-activity relationships among a library of related compounds...
  8. ncbi MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds
    Kiyoshi Nakayama
    Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co, Ltd, 1 16 13, Kitakasai, Edogawa, Tokyo 134 8630, Japan
    Bioorg Med Chem Lett 13:4205-8. 2003
    ....